Everyone knows real-world evidence (RWE) has value. But due to technology challenges, biopharma companies are struggling to achieve the full benefit of their RWE programs. Databricks recently surveyed 109 executives to get a better idea of what’s working, what’s not and the path forward.
Get the full results in this whitepaper. You’ll find out:
- What benefits are driving investments in RWE programs
- Which new types of real-world data will emerge in the next two years
- The top factors inhibiting and contributing to RWE program success
- How to build the ideal data architecture to unlock business outcomes with RWE